MedTrace Logo

Cilostazol and Endothelial Progenitor Cell

NCT04407312 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-29

No results posted yet for this study

Summary

To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)

Conditions

  • Myocardial Infarction, Acute

Interventions

DRUG

Cilostazol Tablets

Cilostazol-SR, capsule, 200mg, once daily, 30 days.

DRUG

placebo

Placebo, tablet, 200mg, once daily, 30 days.

DRUG

Aspirin

Astrix, capsule,100mg, once daily, 30 days.

DRUG

Clopidogrel

Plavix, tablet, 75mg, once daily, 30 days.

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Gyeongsang National University Hospital

    lead OTHER

Principal Investigators

  • Young-Hoon Jeong, MD,.PhD · Gyeongsang National University Changwon Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-12-31
Completion
2020-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407312 on ClinicalTrials.gov